An Open Label Phase I Substudy to Evaluate the Safety and Ability to Enhance Immunogenicity of VXA-A1.1 by Delivery Directly to the Ileum Using the InteliSite Companion Capsule in Healthy Adult Males

Trial Profile

An Open Label Phase I Substudy to Evaluate the Safety and Ability to Enhance Immunogenicity of VXA-A1.1 by Delivery Directly to the Ileum Using the InteliSite Companion Capsule in Healthy Adult Males

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2014

At a glance

  • Drugs VXA-A1-1 (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Acronyms ICC H1
  • Sponsors Vaxart
  • Most Recent Events

    • 09 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 28 Jan 2014 Planned End Date changed from 1 Feb 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
    • 28 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top